Granules India is currently trading at Rs 119.20, up by 2.25 points or 1.92% from its previous closing of Rs. 116.95 on the BSE.
The scrip opened at Rs 119.80 and has touched a high and low of Rs 123.00 and Rs 118.15 respectively. So far 154165 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 164.45 on 01-Dec-2015 and a 52 week low of Rs. 75.20 on 28-Apr-2015.
Last one week high and low of the scrip stood at Rs 125.90 and Rs 102.30 respectively. The current market cap of the company is Rs. 2547.55 crore.
The promoters holding in the company stood at 49.46% while Institutions and Non-Institutions held 6.95% and 43.59% respectively.
Granules India’s wholly owned subsidiary -- Granules USA has entered into an agreement with Par Pharmaceutical Inc., a subsidiary of Endo International plc, to market the generic version of OTC omeprazole and sodium bicarbonate in North America following approval by the U.S. Food and Drug Administration's, which is currently expected in July 2016.
Par Pharmaceutical's omeprazole and sodium bicarbonate is the generic equivalent of Merck/MSD Consumer Care, Inc's Zegerid OTC. Omeprazole is a proton pump inhibitor (PPI) that decreases the production of stomach acid. Sodium bicarbonate is an antacid that raises stomach pH to keep the omeprazole from breaking down in stomach acid.
Granules India is a fast growing pharmaceutical manufacturing company with world class facilities and is committed to manufacturing excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets. The company's global presence extends to over 300 customers in 60 countries through offices in India, U.S., U.K., China and Colombia.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1786.05 |
| Dr. Reddys Lab | 1354.20 |
| Cipla | 1470.05 |
| Lupin | 2190.50 |
| Zydus Lifesciences | 1004.05 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
